https://brandessenceresearch.com/ Logo

Retinal Vein Occlusion Market

Retinal Vein Occlusion Market Size, Share & Trends Analysis Report

Retinal Vein Occlusion Market Size By Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO)), By Condition (Ischemic, Non-Ischemic), By Diagnosis (Fundoscopic Examination, Optical Coherence Tomography (OCT), Fluorescein Angiography, Others), By Treatment (Anti-Vascular Endothelial Growth Factor Drugs, Corticosteroid Drugs, Pan-Retinal Photocoagulation Therapy, Laser Therapy, Others), By End User (Hospitals, Ophthalmic Clinics & Research Centers, Others) Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 – 2027

Published
Report ID : BMRC 1461
Number of pages : 300
Published Date : Nov 2022
Category : Healthcare
Delivery Timeline : 48 hrs

Retinal Vein Occlusion Market is valued at USD 1.27 Billion in 2017 and expected to reach USD 3.23 Billion by 2027 with the CAGR of 9.8% over the forecast period.

Global Retinal Vein Occlusion Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027Increasing prevalence of diabetes, as well as rising incidence of glaucoma, lymphoma, and multiple myeloma across the globe are expected to boost the Retinal vein occlusion market.

Scope of Global Retinal Vein Occlusion Market Report:

Retinal vein occlusion occurs due to blood clot in retinal vein which obstruct the blood flow to retina. It may also cause due to the narrow retinal veins which limits the blood flow to retina. Retinal vein occlusion is one of the most common causes of visual impairment on a global level. The blood clot led to the retinal vein blockage which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. There are two major types of retinal vein occlusion which includes blockage of the central retinal vein causes due to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) causes due to the blockage of smaller branches of veins of the retina. The major causes of retinal vein occlusion are atherosclerosis, hypertension, and eye conditions such as glaucoma and vitreous hemorrhage.

The Global Retinal Vein Occlusion Market has been segmented into condition, type, diagnosis, treatment, end-user   region & country level. By type, the market has been segmented into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Based on the condition, the market has been divided into ischemic and non-ischemic. Based on diagnosis, the market has been segmented into fundoscopic examination, optical coherence tomography (OCT), fluorescein angiography, and others. By treatment, the market has been classified as anti-vascular endothelial growth factor drugs, corticosteroid drugs, pan-retinal photocoagulation therapy, laser therapy, and others. By end-user, the retinal vein occlusion market is classified into hospitals, ophthalmic clinics & research centers, and others.

The regions covered in Global Retinal Vein Occlusion Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Retinal Vein Occlusion Market is sub divided in U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key players for Global Retinal Vein Occlusion Market Report:

Global Retinal Vein Occlusion Market reports cover prominent players like ZEIS, Bristol-Myers Squibb, Ellex Medical Lasers Ltd, GlaxoSmithKline PLC, IRIDEX Corporation, Novartis AG, NIDEK CO., LTD, Allergan PLC, Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc., Topcon Medical Systems, Inc., Bayer, Lumenis and others.

News: Development of new capase-9 inhibitor based eye drops to prevent the vision loss caused due to retinal vein occlusion

June 29th, 2020; Researchers of Columbia University Irving medical center has developed a new eye drop which will prevent vision loss after retinal vein occlusion, a important cause of blindness for millions of adults worldwide. The eye drops consist of highly selective capase-9 inhibitor which improves the blood flow, reduce swelling along with reduced neuronal damage. The researchers are preparing for human clinical trial phase 1.

Global Retinal Vein Occlusion Market Dynamics:

Increasing prevalence of ophthalmic disorders on a global level followed by the growth of geriatric population is expected to anticipate the growth of global retinal vein occlusion market. Additionally, surge in awareness about ophthalmic disorders, improved health care infrastructure, and technological advancements, along with upcoming new treatments are also expected to fuel the growth of global retinal vein occlusion market. Furthermore, increasing incidence of atherosclerosis and diabetes that are recognized as important aspects causing retinal vein occlusion are the key factors driving the growth of the market. Moreover, expanding patient pool suffering from glaucoma, lymphoma, and myeloma is also expected to contribute the growth of retinal vein occlusion market.

However, high cost of treatment and side-effects associated with these treatments are estimated to hamper the market growth over the forecast period. On the other hand, surge in research and investment for the development of safe and economical treatments by market players are expected to create ample opportunities in the market.

Global Retinal Vein Occlusion Market Segmentation:

Global Retinal Vein Occlusion Market: by Type

  • Central retinal vein occlusion (CRVO)
  • Branch retinal vein occlusion (BRVO)

Global Retinal Vein Occlusion Market: by Condition

  • Ischemic
  • Non-ischemic

Global Retinal Vein Occlusion Market: by Diagnosis

  • Fundoscopic examination
  • Optical coherence tomography (OCT)
  • Fluorescein angiography
  • Others

Global Retinal Vein Occlusion Market: by Treatment

  • Anti-vascular endothelial growth factor drugs
  • corticosteroid drugs,
  • pan-retinal photocoagulation therapy
  • Laser therapy
  • Others

Global Retinal Vein Occlusion Market: by End User

  • Hospitals
  • Ophthalmic clinics & research centers
  • Others

Global Retinal Vein Occlusion Market Regional Analysis:

North America is expected to direct the market growth, owing to the increasing prevalence of diabetes, and increasing incidence of diseases such as glaucoma, lymphoma, and multiple myeloma. According to the Centers for Disease Control and Prevention (CDC) in 2017, around 2.7 million people suffer from glaucoma in the US. Similarly, as per American Cancer Society 2018 report, there were around 30,770 new cases of multiple myeloma was diagnosed in the US.

Europe is the second largest region followed by North America in terms of market share. This growth is attributed by various factors such as presence of huge geriatric population along with high healthcare spending. For instance, as per the Organization for Economic Co-operation and Development (OECD) in 2017, the healthcare spending in Germany was USD 5,728 per capita, and the total healthcare spending was around USD 47,1637 million.

The Asia-Pacific region is expected to be the fastest developing region over the forecast period owing to presence of large geriatric population susceptible to various ophthalmic disorders. Moreover, development of healthcare infrastructure as well rising awareness among people with regards to ophthalmic disorders is likely to amplify the market growth in the near future.

  Report Coverage

Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2027
Market Size in 2020: USD 1.27 Billion
Base year considered 2020
Forecast Period CAGR %: 9.80 %
Market Size Expected in 2027: USD 3.23 Billion
Tables, Charts & Figures: 175
Pages 200
Key Players/Companies ZEIS, Bristol-Myers Squibb, Ellex Medical Lasers Ltd, GlaxoSmithKline PLC, IRIDEX Corporation, Novartis AG, NIDEK CO., LTD, Allergan PLC, Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc., Topcon Medical Systems, Inc., Bayer, Lumenis and others
Segments Covered By Type, By Condition, By Diagnosis, by Treatment, by End User
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global Retinal Vein Occlusion Market Report:

  • Global Retinal Vein Occlusion Market report covers in depth historical and forecast analysis.
  • Global Retinal Vein Occlusion Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
  • Global Retinal Vein Occlusion Market report helps to identify opportunities in market place.
  • Global Retinal Vein Occlusion Market report covers extensive analysis of emerging trends and competitive landscape.

Retinal Vein Occlusion Market By Regional & Country Level:

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

Latin America

  • Brazil
  • Mexico

Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Frequently Asked Questions (FAQ) :

ZEIS, Bristol-Myers Squibb, Ellex Medical Lasers Ltd, GlaxoSmithKline PLC, IRIDEX Corporation, Novartis AG, NIDEK CO., LTD, Allergan PLC, Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc., Topcon Medical Systems, Inc., Bayer, Lumenis and others
Increasing prevalence of ophthalmic disorders on a global level followed by the growth of geriatric population is expected to anticipate the growth of global retinal vein occlusion market
Retinal Vein Occlusion Market is valued at USD 1.27 Billion in 2017 and expected to reach USD 3.23 Billion by 2027 with the CAGR of 9.8% over the forecast period.



SUMMARY
VishalSawant
Vishal Sawant
Business Development
vishal@brandessenceresearch.com
+91 8830 254 358
Segmentation
Segments

Global Retinal Vein Occlusion Market: by Type

  • Central retinal vein occlusion (CRVO)
  • Branch retinal vein occlusion (BRVO)

Global Retinal Vein Occlusion Market: by Condition

  • Ischemic
  • Non-ischemic

Global Retinal Vein Occlusion Market: by Diagnosis

  • Fundoscopic examination
  • Optical coherence tomography (OCT)
  • Fluorescein angiography
  • Others

Global Retinal Vein Occlusion Market: by Treatment

  • Anti-vascular endothelial growth factor drugs
  • corticosteroid drugs,
  • pan-retinal photocoagulation therapy
  • Laser therapy
  • Others

Global Retinal Vein Occlusion Market: by End User

  • Hospitals
  • Ophthalmic clinics & research centers
  • Others
Country
Regions and Country

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherlands
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of MEA
Company
Key Players
  • ZEIS
  • Bristol-Myers Squibb
  • Ellex Medical Lasers Ltd
  • GlaxoSmithKline PLC
  • IRIDEX Corporation
  • Novartis AG
  • NIDEK CO.LTD
  • Allergan PLC
  • Regeneron Pharmaceuticals
  • Hoffmann-La Roche AG
  • Quantel Medical Inc.
  • Topcon Medical Systems Inc.
  • Bayer
  • Lumenis
  • and others.

+44-1173181773

sales@brandessenceresearch.com

We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com

JOIN US

LONDON OFFICE

BrandEssence® Market Research and Consulting Pvt ltd.

124, City Road, London EC1V 2NX

FOLLOW US

Twitter
Facebook
LinkedIn
Skype
YouTube

CONTACT US

1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE

© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®

PaymentModes